Figen Batioğlu1, Neslihan Astam, Emin Ozmert. 1. Department of Ophthalmology, Ankara University School of Medicine, Mamak yolu, Dikimevi, 06100, Ankara, Turkey. fbatioglu@gmail.com
Abstract
BACKGROUND: Intravitreal injections of bevacizumab have been reported to have anatomical and functional success in treating choroidal neovascularization, macular edema and neovascular glaucoma. We report a case with neovascular glaucoma due to central retinal vein occlusion who demonstrates rapid resolution of anterior and posterior segment neovascularization after a single intravitreal bevacizumab injection. CASE: A 46-year old man with a 6-month history of central retinal vein occlusion presented with neovascular glaucoma. Fluorescein angiography revealed marked leakage from new vessels on the iris, disc and retina. Bevacizumab was used after incomplete panretinal photocoagulation because of inadequate fundus visualization. About a week after intravitreal bevacizumab injection, new vessels were no longer visible. IOP improved and additional laser photocoagulation was performed. CONCLUSION: Intravitreal bevacizumab injection may be a useful alternative or adjuvant treatment for patients with neovascular glaucoma in whom inadequate visualization precludes adequate panretinal photocoagulation.
BACKGROUND: Intravitreal injections of bevacizumab have been reported to have anatomical and functional success in treating choroidal neovascularization, macular edema and neovascular glaucoma. We report a case with neovascular glaucoma due to central retinal vein occlusion who demonstrates rapid resolution of anterior and posterior segment neovascularization after a single intravitreal bevacizumab injection. CASE: A 46-year old man with a 6-month history of central retinal vein occlusion presented with neovascular glaucoma. Fluorescein angiography revealed marked leakage from new vessels on the iris, disc and retina. Bevacizumab was used after incomplete panretinal photocoagulation because of inadequate fundus visualization. About a week after intravitreal bevacizumab injection, new vessels were no longer visible. IOP improved and additional laser photocoagulation was performed. CONCLUSION: Intravitreal bevacizumab injection may be a useful alternative or adjuvant treatment for patients with neovascular glaucoma in whom inadequate visualization precludes adequate panretinal photocoagulation.
Authors: Jayter Silva Paula; Rodrigo Jorge; Rogério Alves Costa; Maria de Lourdes V Rodrigues; Ingrid U Scott Journal: Acta Ophthalmol Scand Date: 2006-08
Authors: Stephan Michels; Philip J Rosenfeld; Carmen A Puliafito; Erin N Marcus; Anna S Venkatraman Journal: Ophthalmology Date: 2005-06 Impact factor: 12.079
Authors: Fairooz Kabbinavar; Herbert I Hurwitz; Louis Fehrenbacher; Neal J Meropol; William F Novotny; Grazyna Lieberman; Susan Griffing; Emily Bergsland Journal: J Clin Oncol Date: 2003-01-01 Impact factor: 44.544
Authors: Ciro Costagliola; Ugo Cipollone; Michele Rinaldi; Michele della Corte; Francesco Semeraro; Mario R Romano Journal: Br J Clin Pharmacol Date: 2008-11 Impact factor: 4.335
Authors: Carlos Gustavo Vasconcelos de Moraes; Antonio Carlos Facio; José Humberto Costa; Roberto Freire Santiago Malta Journal: J Ocul Biol Dis Infor Date: 2009-03-31